Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.

Lilleskare, Susanne; Vorland, Marta; Vo, Anh Khoi; Aarsand, Aasne K; Reikvam, Håkon

Lilleskare, Susanne; Vorland, Marta; Vo, Anh Khoi; Aarsand, Aasne K; Reikvam, Håkon.

Afiliação

Lilleskare S; Department of Medicine, Stavanger University Hospital, Stavanger, Norway.
Vorland M; Department of Cancer Genomics, Haukeland University Hospital, Bergen, Norway.
Vo AK; Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Aarsand AK; Norwegian Porphyria Centre and Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
Reikvam H; Norwegian Organization for Quality Improvement of Laboratory Examinations, Haraldsplass Deaconess Hospital, Bergen, Norway.

Scand J Clin Lab Invest ; 83(1): 3-7, 2023 02.

Article em En | MEDLINE | ID: mdl-36476017

Assuntos

Calreticulina; Janus Quinase 2; Transtornos Mieloproliferativos; Receptores de Trombopoetina; Humanos; Hemoglobinas; Janus Quinase 2/genética; Janus Quinase 2/metabolismo; Mutação; Transtornos Mieloproliferativos/diagnóstico; Transtornos Mieloproliferativos/genética; Policitemia Vera/genética; Mielofibrose Primária/genética; Receptores de Trombopoetina/genética; Receptores de Trombopoetina/metabolismo; Calreticulina/metabolismo

Palavras-chave

CALR; JAK2; MPL; essential thrombocytosis; polycytemia vera; primary myelofibrosis; smokers

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Calreticulina / Janus Quinase 2 / Receptores de Trombopoetina / Transtornos Mieloproliferativos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google